New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Vitruvia Medical AG · ISIN: CH0461931419 · EQS - Company News (21 News)
Country: Germany · Primary market: Switzerland · EQS NID: 1214375
01 July 2021 10:33AM

Vitruvia Medical's first Circular Clinic Supply Center for robotic instruments goes live with first customers


DGAP-News: Vitruvia Medical AG / Key word(s): Corporate Action/Agreement
Vitruvia Medical's first Circular Clinic Supply Center for robotic instruments goes live with first customers

01.07.2021 / 10:33
The issuer is solely responsible for the content of this announcement.


Vitruvia Medical's first Circular Clinic Supply Center for robotic instruments goes live with first customers

Schönebeck, July 1, 2021 - Vitruvia is the first European service provider to specialize in circular systems for highly complex medical devices. On a site of 2,000 sqm located in Schönebeck, near Magdeburg, Vitruvia has now opened a Circular Clinic Supply Center for robotic instruments. After two years of renovations and upgrades, the center is finally set to begin cleaning and sterilizing hospital instruments under cleanroom conditions, before preparing them for reuse.

Robot-assisted surgery is becoming increasingly common in hospitals. It is now part of surgical medicine, especially for minimally invasive procedures such as complex cancer surgery, and provides substantial benefits, not least of which are greater precision, reduced risk of complications, and faster recovery times.

The complex robotics instruments are designed for reuse. Hospitals currently still perform the complicated reprocessing regime in-house, which requires high investment costs and maintaining the highest hygiene and process quality standards. In addition, there is the risk of underutilized equipment.

Vitruvia Medical is dedicated to providing innovative circular systems for highly complex medical devices so as to minimize patient risks, effectively save resources and help hospitals to achieve higher value added.

Using state-of-the-art processes and technologies, the first European Circular Clinic Supply Center for robotic instruments established by Vitruvia boasts numerous highly specialized devices, such as ultrasonic baths for cleaning instruments used in robot-assisted surgery and advanced testing equipment for sensitive scopes, along with electronic measurement systems and sensor-controlled process monitoring facilities. Progress is also made with self-learning methods in the area of artificial intelligence (AI).

"Every device is returned to the hospital from which it came," explains Rainer Grabow, Managing Director of Vitruvia. "At the same time, an integrated quality management system (iQ) and comprehensive documentation enables hospitals to provide proof of the individual process steps at any time." The hospitals therefore meet all relevant standards currently in force in the European Union and in the Federal Republic of Germany.

From the start, the center has met with a good response among hospitals. The first customers are already on board and include a private hospital operator with 200 beds in the Munich area, a specialist urology clinic, and a hospital group with several facilities in Saxony-Anhalt. The contract values have not been disclosed.

"We believe that the circular systems will help save resources in medical technology, but more so, they are a key factor in enabling medical advances and preventing a two-tier approach to medicine," explains Torsten Cejka, who serves on the Board of Directors of the Swiss-German Vitruvia Medical AG. The hospital service provider therefore plans to expand its service portfolio gradually from robotics to other highly complex medical devices.

Further information: www.vitruvia-med.com

Press contact:
Vitruvia Medical AG
Markus A. Bertschin
Board of Directors
Tel: +41 44 915 33 78
bertschin@vitruvia-med.com



01.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vitruvia Medical AG
Kesselackerstr. 18
5611 Anglikon
Germany
Phone: +41 44 915 33 78
E-mail: welcome@vitruvia-med.com
Internet: www.vitruvia-med.com
ISIN: CH0461931419
Listed: Regulated Unofficial Market in Munich
EQS News ID: 1214375

 
End of News DGAP News Service

1214375  01.07.2021 

fncls.ssp?fn=show_t_gif&application_id=1214375&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.